These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 2219071)

  • 1. [Treatment of heart failure with angiotensin converting enzyme inhibitors].
    Svarstad E; Iversen BM
    Tidsskr Nor Laegeforen; 1990 Sep; 110(22):2896-9. PubMed ID: 2219071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure.
    Suki WN
    Arch Intern Med; 1989 Mar; 149(3):669-73. PubMed ID: 2537612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of heart failure with angiotensin converting enzyme inhibitors. Effects on renal function].
    Osterziel KJ; Dietz R; Kübler W
    Dtsch Med Wochenschr; 1989 Jul; 114(27):1082-5. PubMed ID: 2661192
    [No Abstract]   [Full Text] [Related]  

  • 5. [Modification of hemodynamics by angiotensin converting enzyme inhibitors in heart failure].
    Ertl G; Gaudron P; Eilles C
    Herz; 1990 Jun; 15(3):158-63. PubMed ID: 2198216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure.
    Packer M
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):66-73. PubMed ID: 3037891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ACE inhibition in heart failure and compromised kidney function].
    Drexler H
    Klin Wochenschr; 1991; 69 Suppl 24():59-64. PubMed ID: 1865634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
    Packer M
    Circulation; 1988 Jun; 77(6 Pt 2):I64-73. PubMed ID: 2967129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal function after administration of angiotensin-converting enzyme inhibitors].
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Schweiz Med Wochenschr; 1987 Sep; 117(37):1359-62. PubMed ID: 3672075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal effects of angiotensin converting enzyme inhibitors in heart failure: a clinician's guide to minimizing azotemia and diuretic-induced electrolyte imbalances.
    Weinberg MS
    Clin Ther; 1993; 15(1):3-17; discussion 2. PubMed ID: 8458051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R; Faraone R; Ruggenent P; Remuzzi G
    J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Converting enzyme inhibitors and aims of the objectives of the treatment of cardiac failure].
    Komajda M
    Rev Prat; 1992 Dec; 42(20):2557-61. PubMed ID: 1299940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.
    Tomiyama H; Watanabe G; Abe M; Okazaki R; Yoshida H; Doba N
    Am Heart J; 2001 Mar; 141(3):422-7. PubMed ID: 11231440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic prospects of renin-angiotensin system inhibition.
    Corvol P
    Clin Exp Hypertens A; 1989; 11 Suppl 2():463-70. PubMed ID: 2691125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.